DTIL Stock Overview
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States.
Precision BioSciences, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.34|
|52 Week High||US$9.41|
|52 Week Low||US$1.11|
|1 Month Change||-4.29%|
|3 Month Change||-14.65%|
|1 Year Change||-83.64%|
|3 Year Change||-93.18%|
|5 Year Change||n/a|
|Change since IPO||-92.32%|
Recent News & Updates
Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its DebtApr 19
Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)Mar 21
Precision BioSciences (NASDAQ:DTIL) Is Using Debt SafelyDec 31
Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?Sep 24
Analysts Are Betting On Precision BioSciences, Inc. (NASDAQ:DTIL) With A Big Upgrade This WeekJun 08
New Forecasts: Here's What Analysts Think The Future Holds For Precision BioSciences, Inc. (NASDAQ:DTIL)May 20
Analysts Just Made A Major Revision To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Revenue ForecastsMar 23
Could The Precision BioSciences, Inc. (NASDAQ:DTIL) Ownership Structure Tell Us Something Useful?Feb 26
A Look At Precision BioSciences' (NASDAQ:DTIL) Share Price ReturnsJan 04
|DTIL||US Biotechs||US Market|
Return vs Industry: DTIL underperformed the US Biotechs industry which returned -7.4% over the past year.
Return vs Market: DTIL underperformed the US Market which returned -14.9% over the past year.
|DTIL Average Weekly Movement||8.9%|
|Biotechs Industry Average Movement||11.2%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.7%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: DTIL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: DTIL's weekly volatility (9%) has been stable over the past year.
About the Company
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma.
Precision BioSciences, Inc. Fundamentals Summary
|DTIL fundamental statistics|
Is DTIL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DTIL income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.95|
|Net Profit Margin||-505.97%|
How did DTIL perform over the long term?See historical performance and comparison